Larry D. Anderson Jr., UT Southwestern Medical Center (IMAGE)
Caption
A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times, according to an international clinical trial with UT Southwestern as the lead enrolling site.
Credit
UT Southwestern Medical Center
Usage Restrictions
None
License
Licensed content